Profile data is unavailable for this security.
About the company
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.
- Revenue in USD (TTM)862.99m
- Net income in USD318.80m
- Incorporated2007
- Employees373.00
- LocationHalozyme Therapeutics Inc12390 EL CAMINO REALSAN DIEGO 92130United StatesUSA
- Phone+1 (858) 794-8889
- Fax+1 (302) 655-5049
- Websitehttps://www.halozyme.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuvalent Inc | 0.00 | -145.51m | 4.33bn | 106.00 | -- | 6.41 | -- | -- | -2.41 | -2.41 | 0.00 | 10.47 | 0.00 | -- | -- | 0.00 | -24.88 | -- | -26.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Krystal Biotech Inc | 95.95m | 57.16m | 4.54bn | 229.00 | 84.48 | 5.68 | 71.59 | 47.33 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Immunitybio Inc | 302.00k | -600.96m | 4.58bn | 628.00 | -- | -- | -- | 15,159.54 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.92 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 4.76bn | 376.00 | -- | 5.43 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 4.92bn | 702.00 | -- | 18.44 | -- | 9.39 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.21bn | 550.00 | -- | -- | -- | 23.82 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.40bn | 10.00k | 5.15 | 111.83 | 4.18 | 0.8501 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Halozyme Therapeutics, Inc. | 862.99m | 318.80m | 5.48bn | 373.00 | 17.82 | 30.82 | 13.68 | 6.35 | 2.42 | 2.42 | 6.54 | 1.40 | 0.4874 | 1.34 | 4.42 | 2,313,644.00 | 18.01 | 18.22 | 19.22 | 21.97 | 78.50 | 79.05 | 36.94 | 39.36 | 5.36 | 966.62 | 0.8941 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.49bn | 927.00 | -- | 18.51 | -- | 7.07 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 5.52bn | 423.00 | -- | -- | -- | 1,472.23 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Exelixis Inc | 1.85bn | 205.05m | 5.92bn | 1.31k | 31.46 | 2.82 | 25.73 | 3.21 | 0.6466 | 0.6466 | 5.84 | 7.21 | 0.621 | 3.12 | 7.78 | 1,409,653.00 | 6.90 | 8.86 | 7.82 | 9.91 | 95.70 | 96.30 | 11.10 | 15.43 | 3.41 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Revolution Medicines Inc | 4.57m | -484.27m | 6.25bn | 411.00 | -- | 3.62 | -- | 1,369.47 | -3.76 | -3.76 | 0.035 | 10.46 | 0.0031 | -- | 2.29 | 12,079.37 | -32.48 | -29.76 | -34.18 | -32.59 | -- | -- | -10,606.04 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Blueprint Medicines Corp | 282.21m | -288.29m | 6.41bn | 645.00 | -- | 20.62 | -- | 22.71 | -4.82 | -4.82 | 4.59 | 4.96 | 0.2499 | 0.3531 | 6.18 | 430,853.40 | -25.53 | -29.92 | -30.68 | -34.06 | 96.97 | -- | -102.15 | -116.65 | 3.61 | -23.37 | 0.4352 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Jazz Pharmaceuticals PLC | 3.84bn | 330.79m | 6.62bn | 2.80k | 21.67 | 1.79 | 6.77 | 1.72 | 4.85 | 4.85 | 55.49 | 58.65 | 0.3436 | 0.6428 | 5.78 | 1,372,634.00 | 2.99 | 1.48 | 3.36 | 1.62 | 89.53 | 88.79 | 8.69 | 4.26 | 1.90 | 1.87 | 0.607 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
Data as of May 28 2024. Currency figures normalised to Halozyme Therapeutics Inc's reporting currency: US Dollar USD
44.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 15.35m | 12.08% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 12.67m | 9.97% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 6.49m | 5.11% |
| Snyder Capital Management LPas of 31 Mar 2024 | 4.12m | 3.24% |
| Artisan Partners LPas of 31 Mar 2024 | 3.79m | 2.98% |
| AllianceBernstein LPas of 31 Mar 2024 | 3.67m | 2.89% |
| Geode Capital Management LLCas of 31 Mar 2024 | 3.03m | 2.38% |
| Macquarie Investment Management Business Trustas of 31 Mar 2024 | 2.99m | 2.35% |
| TD Asset Management, Inc.as of 31 Mar 2024 | 2.54m | 2.00% |
| GW&K Investment Management LLCas of 31 Mar 2024 | 2.20m | 1.73% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
